The optimum approach for the treatment of rare anaplastic gliomas following surgical resection is uncertain. A recent study has now provided a greater understanding of the heterogeneous tumor biology of these tumors and has emphasized the prognostic importance of chromosome 1p19q deletion, IDH mutation and MGMT promoter methylation. The importance of radiotherapy and chemotherapy for treating these heterogeneous tumors is being elucidated for subgroups of patients.
Access options
Subscribe to Journal
Get full journal access for 1 year
$59.00
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
References
- 1
Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).
- 2
van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J. Clin. Oncol. 24, 2715–2722 (2006).
- 3
Cairncross, G. et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial. J. Clin. Oncol. 24, 2707–2714 (2006).
- 4
Wick, W. et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27, 874–880 (2009).
- 5
van den Bent, M. J. et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 16, 1597–1604 (2010).
- 6
DeAngelis, L. M. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. J. Clin. Oncol. 27, 861–862 (2009).
- 7
Cairncross, G. et al. A randomized trial of chemotherapy plus radiotherapy (RT) versus RT alone for anaplastic oligodendroglioma (RTOG 9402): the perspective of longer follow-up [abstract 16]. Int. J. Radiat. Oncol. Biol. Phys. 72, S7–S8 (2008).
- 8
Abrey, L. E. et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro-oncol. 9, 314–318 (2007).
- 9
US National Library of Medicine. ClinicalTrials.gov [online], (2010).
- 10
US National Library of Medicine. ClinicalTrials.gov [online], (2010).
Author information
Affiliations
Corresponding author
Ethics declarations
Competing interests
P. G. Morris has received honoraria from the following companies: Eisai, Genomic Health, Pfizer, Haymarket Media Group, Bristol-Myers Squibb, Genentech, Novartis and Centocor Ortho Biotech. A. B. Lassman acts as a consultant for, and has received honoraria and research support from, Merck & Co. He has received research support from Keryx Biopharmaceuticals, Sigma Tau Pharmaceuticals and Genentech and acts as a consultant for Genentech, Eisai, ImClone and Cephalon.
Rights and permissions
About this article
Cite this article
Morris, P., Lassman, A. Optimizing chemotherapy and radiotherapy for anaplastic glioma. Nat Rev Clin Oncol 7, 428–430 (2010). https://doi.org/10.1038/nrclinonc.2010.98
Issue Date:
Further reading
-
Overexpressed P75CUX1 promotes EMT in glioma infiltration by activating β-catenin
Cell Death & Disease (2021)
-
Predicting the efficiency of polyethylene glycol-functionalised graphene in delivery of temozolomide anticancer drug and investigating the effect of pH on the drug release process: DFT and free energy calculations
Molecular Simulation (2020)
-
Effects of small nucleolar RNA SNORD44 on the proliferation, apoptosis and invasion of glioma cells
Histochemistry and Cell Biology (2020)
-
Outside-in synthesis of mesoporous silica/molybdenum disulfide nanoparticles for antitumor application
Chemical Engineering Journal (2018)
-
Multifunctional carbon nanomateriels for camptothecine low-water soluble anticancer drug delivery
New Journal of Chemistry (2018)
